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Human platelets may hydrolyze externally added NAD+ yielding ADPR and nicotinamide. The extent of 
hydrolysis is significantly higher when the platelets are stimulated. The presence of external NAD+ strongly 
inhibits the aggregation induced by every agonist used. It seems that adenosine or ADPR itself generated 
by NAD+ hydrolysis may be responsible for the inhibition of aggregation. Evidence is given that some of 
the NAD+ hydrolysis product is taken up by stimulated platelets. 
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1. INTRODUCTION 
NADase (NAD+ glycohydrolase EC 3.2.2.5) is 
an enzyme which hydrolyzes NAD+ at the 
nicotinamide-ribose bond. The presence of 
NADase in mitochondrial and plasma membranes 
of many cells has been reported. Several NADases 
have been identified as ADP-ribosyltransferase 
and poly(ADP-ribose) polymerase [ 1,2]. It has 
been suggested that the biochemical role of 
NADase is the regulation of certain metabolic pro- 
cesses through a control of the quantity of NAD+ 
available to the NAD+-dependent enzymes 131. On 
the other hand it has been reported that NADases 
are ecto-enzymes in several cell types. For exam- 
ple, NADases from erythrocytes and macrophages 
are associated with the cell surface [4,5]. This 
evidence suggests a role of these enzymes in 
membrane-associated events, such as agonist- 
receptor interactions or in the transduction of ex- 
ternal stimuli to the cell interior. 
Deficiency of erythrocyte NADase has been 
reported in human subjects [6]. This deficiency 
was not apparently accompanied by clinical symp- 
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toms. Therefore the function of NADase in red 
cells is not yet known. 
In the present paper we report on the presence of 
NADase in human blood platelets and its involve- 
ment in platelet function. 
2. MATERIALS AND METHODS 
The chemicals were from commercial sources 
and used without further purification. Platelets 
were prepared from blood samples obtained from 
healthy donors not taking any drugs for at least 20 
days, after informed consent. Blood, collected in 5 
mM EDTA, was centrifuged at 1OOxg for 15 min. 
Residual polymorphonuclear cells were eliminated 
by centrifuging plasma through a Ficoll layer 
(23%) w/v) at 80x g for 20 min. Further cen- 
trifugation of platelet-rich plasma at 1200xg for 
15 min gave a platelet-containing pellet, which was 
resuspended in Dulbecco’s PBS, pH 7.4, to a con- 
centration of 3.3 x 10’ platelets/ml. These platelet 
preparations contained less than 1 polymor- 
phonuclear cell/ 10’ platelets [7]. Fibrinogen (1 
mg/ml) and CaClz (1 mM) were added and then 
platelet aggregation was monitored after addition 
of appropriate stimuli by the change in light 
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transmission at 650 nm in a standard platelet ag- 
gregometer (Aggrecoder PA-3210, Menarini, 
Firenze, Italy), according to the method of Born 
[8]. The agonists used were ADP (2 FM), collagen 
(2 PM/ml), adrenaline (0.5 ,uM), y-thrombin (0.5 
U/ml) and calcium ionophore A23187 (20 PM). 
ADP-ribosylation was measured as the incor- 
poration of [H 2,8-adenine-3H]NAD+ into intact 
cells, according to Berger et al. [9]. The disap- 
pearance of added NAD+ was assayed using an en- 
zymatic method based on alcohol dehydrogenase 
as described [lo]. In some experiments the disap- 
pearance of NAD+ was measured by 
isotachophoresis. The experimental conditions of 
this technique have been reported [ll]. This 
method monitors both oxidized and reduced forms 
of pyridine nucleotides. 
HPLC of supernatants from platelet suspen- 
sions was performed using a Perkin Elmer Series 3 
liquid chromatograph, equipped with an LC 55 B 
spectrophotometric detector and an SC 55 S digital 
scanner and a Perkin Elmer 023 recorder. Integra- 
tion of peak areas was achieved by means of a 
Hewlett-Packard mod. 3390 A integrating 
recorder. A Hibar-Merck RP-18 RT-250-4 10 pm 
column was used with the following solvent 
systems: solvent A, 0.01 M aqueous tetraethyl am- 
monium chloride (150 ml) and MeCN (350 ml); 
solvent B, 70 mM NaH2P04 and 10 mM tetraethyl 
ammonium chloride in redistilled water. Solvents 
(HPLC grade) were filtered through Millipore 
HAW 0.45 pm filters and degassed under vacuum 
10 min before use. 
The following solvent program was used: (i) an 
isocratic step (2 min) at 3% solvent A: (ii) a linear- 
ly increasing gradient (10 min) from 3 to 10% sol- 
vent A; (iii) an isocratic step (8 min) at 10% solvent 
A; (iv) a purge step (5 min) at 50% solvent A (used 
every 8-10 injections); (v) an equilibration step (10 
min) at the initial percentage of solvent A. 
Sample elution was monitored at 260 nm and 
peak retention times neglecting the dead volume of 
the column are given. UV spectra of the single 
peaks were taken by means of a stop-flow tech- 
nique with a scan rate of 120 nm/min, after 
background calibration. Identification of 
nucleotides and their degradation products was 
achieved by comparing them with authentic 
samples in the same eluting conditions or by using 
internal standards. The supernatant of platelet 
suspensions incubated in 100 mM phosphate buf- 
fer solution, pH 7.2, containing 500 ,uM NAD+ 
(final concentration) obtained after centrifugation 
at 1200xg for 10 min, was analyzed on the 
chromatograph (sample volume size, 10 ~1). An 
ethanolic extract of the lyophilized samples (1 ml 
four extractions with 5 ml of 95% EtOH) was 
made to enrich nicotinamide from the starting mix- 
tures. EtOH was then evaporated under vacuum 
and the residue redissolved in 0.5 ml H20 (sample 
volume size, 40 ~1). 
3. RESULTS 
The addition of 500 FM NAD+ to platelet 
suspensions trongly reduced the aggregation in- 
duced by agonists like ADP, collagen, adrenaline, 
thrombin and A23 187 (fig. 1). This finding induced 
us to ascertain whether NAD+ was transformed 
during the process. In fact, the supernatant of 
stimulated platelets howed, by isotachophoresis, a
reduction of the peak corresponding to NAD+ 
when compared to the supernatant of resting 
platelets (not shown). The disappearance of added 
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Fig.1. Effect of NAD+ on the aggregation of platelets. 
Platelet suspensions (3.3 x lo* cells/ml) in PBS contain- 
ing 1 mg/ml fibrinogen and 1 mM CaC12 were 
stimulated in the absence (a) and presence of 500 ,uM 
NAD+ (b) or of 500 pM NADP+ (c). The stimuli used 
were: (A) 2 pM ADP; (B) 0.5 PM epinephrine; (c) 2 
pg/ml collagen; (D) 20 pM A23187; (E) 0.5 U/ml y- 
thrombin . 
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NAD+ from the supernatant of stimulated 
platelets was also found by testing it in the alcohol 
dehydrogenase reaction. Using [2,8-adenine-3H]- 
NAD+ it was found that some radioactivity was in- 
corporated into platelets (fig.2). This radioactivity 
was acid labile, i.e., non-covalently bound to 
platelets. In fact trichloroacetic acid-treated and 
washed platelet pellet did not have significant 
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Fig.2. Uptake of [2,8-adenine-3H]NAD+ by stimulated 
platelets. The platelet suspension (3.3 x lOa cells/ml) 
was stimulated in the presence of 1 ,&i of labeled NADf 
diluted within 1 mM NAD+. Bars: (A) resting platelets, 
time zero; (B) resting platelets after 20 min incubation at 
37°C; (C) platelets stimulated with 2 pg/ml collagen 
after 20 min incubation at 37°C; (D) platelets stimulated 
with 2 pg/ml collagen in the presence of 0.01 U/ml 
phosphodiesterase; (E) trichloroacetic acid (10%) 
precipitate of C. 
Table 1 
Adenosine uptake by stimulated platelets 
Incubation time Thrombin Adenosine found in 
(min) (0.5 U/ml) the supernatant 
01M) 
0 _ 500 f 10 
0 + 470 f 10 
20 _ 480 f 20 
20 + 450 f 5 
To platelet suspensions (3.3 x 10’ cell/ml) 500 PM 
adenosine was added at zero time. Where indicated 
thrombin was added. Each determination made at least 
in triplicate. Values are expressed as mean + SD. These 
values were determined from the area of the HPLC 
Fig.3. HPLC of NAD+ in the presence of platelets. Up- 
per panel: elution profile of a supernatant of platelet 
suspension (6 x lo9 cells) in 0.1 M PBS, pH 7.2, contain- 
ing 5OOpM NAD+, centrifuged at 1200 x g at 4”C, im- 
mediately after the addition of NAD+. Absorbance is 
given in percent of full scale (see section 2). Lower panel: 
same as above, but after 30 min incubation at 37°C in 
the presence of 500 pM NAD+ before centrifugation. 
Dashed line represents the corresponding elution profile 
peaks of the ethanolic extract of a freeze-dried sample. 
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bound radioactivity. Instead, more radioactivity 
was taken up into platelets by adding snake venom 
phosphodiesterase to the incubation mixture. 
Control experiments showed that stimulated 
platelets were also able to take up externally added 
adenosine. Table 1 shows that in 20 min about 
10% of the adenosine initially present disappeared 
from the suspensions of platelets stimulated by 
ADP, but not from the suspensions of resting 
platelets. 
The fate of NAD+ incubated with stimulated 
platelets was checked by HPLC. Fig.3 shows the 
decrease of the peak corresponding to NAD+ in 
the supernatant of stimulated platelets and the for- 
mation of new peaks. Two of them have been iden- 
tified as nicotinamide and ADPR by comparison 
with authentic compounds. Thus NAD+ appears 
to be hydrolyzed in an NADase reaction catalyzed 
by activated platelets. 
The addition of 10 mM nicotinamide to the in- 
cubation mixture, containing activated platelets 
and NAD+ reduced the extent of hydrolysis by 
40-50%, further confirming the presence of an 
NADase activity [12]. The rate of NAD+ 
hydrolysis was about 100 nmol/108 platelets per 20 
min. This rate was about 60-70% lower than that 
obtained with the same amount of platelet 
homogenate. NADH and NADPH were not 
significantly hydrolyzed. 
To check whether the inhibitory effect of NAD+ 
on the aggregation was related to NAD+ itself or 
rather to its hydrolysis products, the following 
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Fig.4. Effect of nicotinamide, ADPR and adenosine on 
platelet aggregation induced by y-thrombin. Curves: (a) 
y-thrombin alone (0.5 U/ml); (b) + NAD+ (5OOpM); (c) 
+ adenosine (5OOpM); (d) + nicotinamide (SOO~M); (e) 
+ ADPR (500 pM). Other conditions as in fig.1, 
controls were made. Nicotinamide did not in- 
fluence the aggregation of platelets, but even 
counteracted the inhibitory effect of NAD+ at the 
same concentrations which inhibited the hydrolysis 
of NAD+. ADPR and adenosine, instead, were 
able to inhibit the aggregation induced by throm- 
bin and by A23187 (fig.4). 
4. DISCUSSION 
The above reported data show that stimulated 
human platelets can hydrolyze NAD+ and to a 
lesser extent NADP+, but not their reduced forms. 
Resting platelets how a much lower, if any, ability 
of hydrolyzing NAD+. The control with resting 
platelets may give erroneous results due to 
unspecific stimulation by mechanical manipulation 
(e.g., pipetting, stirring, etc.). The hydrolysis of 
NAD+ by platelets was inhibited in the presence of 
nicotinamide, which was identified as a product of 
the reaction. These two facts indicate that the 
hydrolytic enzyme is an NADase. As far as the pre- 
sent evidence goes, it appears that this activity is 
not related to ADP-ribosylation, since only free 
ADP-ribose has been detected. Using a radioactive 
NAD+ some radioactivity was found inside 
platelets, but in soluble form. It is still conceivable 
that in vivo the platelets may indeed induce this 
ADP-ribosylation of some extracellular structure. 
Whatever the possible role of NADase toward ex- 
ogenous substrates, it appears that this activity in 
the meantime strongly affects platelet aggregation. 
It is difficult to attribute this effect to a single 
chemical species since ADPR and adenosine, 
which may arise from the latter, both show an in- 
hibitory effect when added to stimulated platelets. 
Adenosine has been already shown to inhibit 
platelet aggregation both in vitro and in vivo [ 131. 
The present study has demonstrated that adenosine 
can be taken up by stimulated, but not by resting 
platelets. The greater radioactivity found inside the 
platelets incubated with NAD+ and 
phosphodiesterase seems to confirm a role of 
adenosine. Furthermore it is also possible that the 
anti-aggregating effect is due to NAD+. It should 
however be pointed out that the simultaneous ad- 
dition of NAD+ and nicotinamide, which strongly 
inhibits the NADase activity, reduces the effect of 
NAD+ on platelet aggregation, then suggesting 
that the hydrolysis of NAD+ is important in the 
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anti-aggregating effect. The presence of NADase 
activity on the cell surface has been reported for 
various cell types [3,14-181. Though the 
physiological meaning of this enzyme is obscure, 
there are reports associating this activity with the 
cell function. The NADase activity of platelets is 
expressed only (or mainly) in stimulated platelets. 
This is clearly at variance with other cells, where 
the activity is always present or even lower after 
stimulation, like macrophages [141. 
In conclusion it appears that platelets are sen- 
sitive to the presence of extracellular NAD+. The 
nicotinamide formed is then methylated. It has 
been suggested that nicotinamide methylation and 
N-methylnicotinamide have growth regulation 
properties as their level is inversely correlated to 
cell proliferation [ 191. This finding further stresses 
the regulatory role of this coenzyme in addition to 
the well known redox ability. 
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